InDex Pharmaceuticals Holding AB (publ)
INDEX.ST
Stockholm Stock Exchange0.56
SEK
+0.02
- -
InDex Pharmaceuticals Holding AB (publ)
INDEX.ST
(Stockholm Stock Exchange)
Recent
price
0.56
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- InDex Pharmaceuticals Holding AB (publ), now operating as Flerie AB and listed under ticker INDEX.ST on Nasdaq First North Growth Market, functions as a Sweden-based life science investment company headquartered in Stockholm and founded in 2000, focusing on active long-term investments in biotechnology, pharmaceuticals, and related services across Europe, Israel, and the US; its portfolio spans three segments including Product Development with early-stage biotech and pharma companies advancing products to clinical proof-of-concept, Commercial Growth featuring revenue-generating entities in sales expansion and mergers, and Limited Partnerships for diversified exposure to specialized funds, encompassing areas such as immuno-oncology, metabolic diseases including obesity and diabetes, heart disease, cancer, autoimmune disorders, biologics manufacturing, diagnostics, medical devices, and tools. The company previously developed immunological disease treatments including the lead drug candidate cobitolimod for moderate-to-severe ulcerative colitis, a platform of DNA-based ImmunoModulatory Sequences (DIMS) for various immunological conditions, and the diagnostic kit DiBiCol, a PCR-based method monitoring seven biomarkers for ulcerative colitis or Crohn's disease from a single biopsy, through subsidiaries InDex Pharmaceuticals AB and InDex Diagnostics AB. In a major 2024 strategic shift, InDex executed a reverse merger by acquiring Flerie Invest AB via issuance of over 6 billion new shares valuing Flerie at SEK 3.1 billion, resulting in Flerie's shareholders holding 91.9% ownership, discontinuation of all prior drug development including cobitolimod, name change to Flerie AB, leadership transition with Ted Fjällman as CEO, uplisting preparations to Nasdaq Stockholm, a SEK 520 million directed share issue from institutional investors like the Fourth Swedish National Pension Fund and HBM Healthcare Investments, and establishment of an annual voluntary share redemption program offering liquidity through convertible series C shares up to 5% of outstanding shares based on net asset value.